Prior to joining Keata, John most recently held the position of President, Draxis Pharma Division of Draxis Health Inc. and was responsible for the divisions pharmaceutical contract manufacturing operations including business development, strategic planning, supply chain and logistics. John is well known in the industry, having held senior positions with Banner Pharmaceuticals, Novartis Canada and McNeil Consumer Products. John holds an Honours BSc. degree in Microbiology from the University of Guelph.

"I am certain that John's extensive management experience and strong health science background will be of great benefit to Keata," said Alan Kwong, CEO of PharmEng International Inc. "His reputation and proven track record in the sector makes him well-suited for his new responsibilities at Keata. He will be a strong addition to the senior management team as we build the book of business for Keata," concludes Mr. Kwong.

Keata manufacturing capabilities include pilot laboratories for formulation development, various capabilities of high shear mixing, container blending and equipment for modified release technology in an environment consistent with current Good Manufacturing Practices. Keata facilities have the necessary equipment and approvals to provide formulation development and testing services to manufacture and package products in solid and liquid dosage forms, including aseptic manufacturing. Keata's long-term goal is to develop capabilities in other dosage forms, such as suppositories, topicals and injectables.

About PharmEng International Inc.

PharmEng International Inc., headquartered in Toronto, Canada, is a full-service consulting and contract manufacturing company that serves the pharmaceutical and biotechnology industries in North America and internationally. Consulting services include project management, engineering, GMP, validation, calibration, regulatory compliance and certified training. Contract manufacturing includes pharmaceutical support, formulation development, laboratory testing, and finished solid dosage and liquid products. PharmEng's shares trade on the TSX Venture Exchange under the symbol PII. For more information about PharmEng International Inc. (TSX VENTURE: PII), visit the Company's website at www.pharmeng.com.

FORWARD LOOKING STATEMENTS

Certain statements in this press release may include "forward-looking" statements which involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of PharmEng to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used in this press release, such statements use such words as "may", "will", "expect", "anticipate", "project", "believe", "plan", and other similar terminology. The risks and uncertainties are detailed from time to time in reports filed by PharmEng with the securities regulatory authorities in all of the provinces and territories of Canada. New risk factors may arise from time to time and it is not possible for management to predict all of those risk factors or the extent to which any factor or combination of factors may cause actual results, performance and achievements of PharmEng to be materially different from those contained in forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction actual results.

Contacts:PharmEng International Inc.Charles IveyVice President(905) 415-3922 x 116Website: www.pharmeng.com